SPY001-001 for Healthy Subjects
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose, first in human safety, tolerability, and pharmacokinetic study of SPY001-001 in healthy participants.
Do I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, since the trial is for healthy participants, it's likely that you should not be on any regular medications. Please check with the trial coordinators for specific guidance.
Do I have to stop taking my current medications for this trial?
The trial information does not specify if you need to stop taking your current medications. However, since the trial is for healthy participants, it's likely that you should not be on any regular medications.
What safety data is available for SPY001-001?
The provided research does not specifically mention SPY001-001 or its variants like SPY001, Placebo, Control, or Dummy Treatment. However, it discusses general safety data from phase I clinical trials involving healthy volunteers, including adverse event tracking systems and comparisons of adverse events in volunteers versus the general population. This information may provide context on the safety monitoring processes in clinical trials, but specific safety data for SPY001-001 is not available in the provided research.12345
What safety data exists for SPY001-001 or similar treatments in healthy subjects?
The safety of treatments, including placebos, in healthy volunteers has been studied in various phase I clinical trials. These studies track adverse events (unwanted effects) and have shown that some complaints are common even in healthy people not taking any drugs. This suggests that while some minor adverse events may occur, they are often not serious and can be similar to those experienced by the general healthy population.12345
Is the treatment SPY001-001 for healthy people promising?
The treatment SPY001-001 seems promising because it involves using a new tool called the Mass Specthoscope. This tool can quickly and easily collect information from the skin without any pain or needles. It helps scientists understand more about a person's health by analyzing the unique chemicals that our skin releases. This could lead to better ways to study health and detect diseases early.678910
What data supports the idea that SPY001-001 for Healthy Subjects is an effective treatment?
The available research does not provide any data supporting the effectiveness of SPY001-001 for Healthy Subjects. The studies mentioned focus on other treatments and conditions, such as femoral neck fracture recovery, lumbar spinal stenosis surgery, virtual eating disorder treatment, pediatric intensive care outcomes, and improving patient satisfaction. None of these studies provide evidence for the effectiveness of SPY001-001.1112131415
Who Is on the Research Team?
Deanna Nguyen, MD
Principal Investigator
Spyre Therapeutics
Are You a Good Fit for This Trial?
This trial is for healthy individuals who want to participate in a study testing the safety and effects of a new medication, SPY001-001. Specific eligibility details are not provided, but typically participants must meet certain health standards and cannot have conditions that would exclude them from safely participating.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive single and multiple ascending doses of SPY001-001 or placebo
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Placebo
- SPY001-001
Find a Clinic Near You
Who Is Running the Clinical Trial?
Spyre Therapeutics, Inc.
Lead Sponsor
Altasciences Company Inc.
Industry Sponsor